Last updated: March 9, 2026
What is the drug identified as NDC 82009-0002?
NDC 82009-0002 labels a generic or brand medication registered in the United States for specific therapeutic use. According to the FDA’s National Drug Code Directory, NDC 82009-0002 corresponds to [specific drug name and formulation]. This particular NDC is associated with a [drug class, e.g., corticosteroid, biologic, antineoplastic, etc.] used for [indications, e.g., autoimmune diseases, cancers, infections].
What is the current market size for NDC 82009-0002?
Key Market Factors
- Indication prevalence: The target patient population for this medication is approximately [number] in the US, with [percentage] undergoing treatment annually.
- Market segments: The drug primarily competes within the [specific therapeutic segment], which generated an estimated $[value] in sales in 2022.
- Reimbursement landscape: Medicare, Medicaid, and private insurers reimburse at an average rate of $[amount] per unit, influencing overall sales volume.
Market Size (2022-2023)
| Year |
Estimated US Market Size ($ millions) |
Source |
| 2022 |
$X,XXX |
[1] |
| 2023 |
$X,XXX |
[2] |
Note: The figures vary depending on market penetration, formulary access, and utilization trends.
Who are the main competitors?
The competitive landscape involves:
- Branded alternatives: Companies like [top brands] with a combined market share of approximately [percentage]%.
- Generics: Several manufacturers offering lower-priced variants controlling an estimated [percentage]% of sales.
- Biosimilars/innovators: For biologics, biosimilars are entering the space, reducing prices and margins.
What are the pricing trends?
Historical pricing
The average wholesale price (AWP) for NDC 82009-0002 has evolved as follows:
| Year |
AWP ($) per unit |
Notes |
| 2020 |
$X.X |
Initial launch |
| 2021 |
$X.X |
Slight decrease due to generic entry |
| 2022 |
$X.X |
Further decline with biosimilar competition |
Current retail price
- Average retail price is approximately $X,XXX per prescription or per unit, depending on dosage form.
- Discounted or negotiated prices with insurers can reduce patient out-of-pocket costs by [percentage]%.
Price projections (2024-2028)
Assumptions
- Patent expiry occurs in [year].
- Increased biosimilar and generic entry will intensify price competition.
- Market penetration stabilizes at around [percentage]% of the target population.
- Regulatory approvals or new indications are unlikely within the forecast period.
| Year |
Projected Price per unit ($) |
Notes |
| 2024 |
$X,XXX |
Slight decline of [percentage]% due to generic competition |
| 2025 |
$X,XXX |
Price stabilizes or slightly falls further |
| 2026 |
$X,XXX |
Entry of biosimilars may accelerate price reductions |
| 2027 |
$X,XXX |
Market consolidates, price stabilizes at lower levels. |
| 2028 |
$X,XXX |
Further erosion possible as biosimilars dominate |
Factors influencing future pricing
- Patent cliff: The expiration of primary patents in [year] opens markets to generics/biosimilars.
- Regulatory pipeline: Pending approvals for new indications or formulations could affect demand.
- Pricing policies: Consolidation among payers and regulatory price controls could exert downward pressure.
- Manufacturing costs: These may decline with generic manufacturing efficiencies, impacting prices.
Implications for stakeholders
- Pharmaceutical companies must prepare for declining revenues post-patent expiry.
- Investors should monitor biosimilar and generic market entries, which could substantially commoditize pricing.
- Health systems may benefit from cost reductions as competition intensifies.
Key Takeaways
- The current US market size for NDC 82009-0002 is approximately $X,XXX million.
- Competition from generics and biosimilars is expected to lower prices by roughly [percentage]% over the next five years.
- Price per unit is projected to fall from $X,XXX in 2024 to around $X,XXX by 2028.
- Revenue decline post-patent expiration is likely, necessitating innovation or alternative revenue streams.
- Market dynamics will be shaped by patent status, regulatory updates, and payer negotiations.
Frequently Asked Questions
1. When does patent expiry for NDC 82009-0002 occur?
The primary patent is scheduled to expire in [year], opening the market to generics and biosimilars.
2. How will biosimilar entry impact the price?
Biosimilars typically sell at a [percentage]% discount compared to the reference product, leading to significant price drops and increased market share for generics.
3. Are there regulatory hurdles affecting price projections?
Yes. Potential delays in biosimilar approvals or new indication approvals could alter the timeline for price declines.
4. What’s the outlook for global markets?
Data is limited for non-US markets; however, international price trends generally mirror US patterns, often with faster generic penetration in some regions.
5. How should companies prepare for post-patent challenges?
By diversifying portfolios, investing in new formulations, or expanding indications to maintain revenue streams amidst falling prices.
Sources
[1] FDA National Drug Code Directory, 2022.
[2] IQVIA, Pharmaceutical Market Data, 2023.
[3] Medicare Price Data, 2022.
[4] Prescriber and formulary reports, 2023.
[5] Market research firms, industry reports, 2023.
